Skip to Content
Merck

Key Documents

View All Documentation

579002

(Z)-4-Hydroxytamoxifen

≥99% (HPLC), solid, estrogen receptor modulator, Calbiochem

Synonym(s):

Tamoxifen, 4-Hydroxy-, (Z)-, (Z)-4-Hydroxytamoxifen, 4-OH-TAM, Estrogen Receptor Signaling Regulator II

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C26H29NO2
CAS Number:
68047-06-3
Molecular Weight:
387.51
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00278780
Assay:
≥99% (HPLC)
Form:
solid
Quality level:
200
Storage condition:
OK to freeze
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Tamoxifen, 4-Hydroxy-, (Z)-, A cell-permeable, active metabolite of Tamoxifen that acts as a potent inhibitor of PKC. It is more potent than the parent compound and inhibits PKC by modifying its catalytic domain.

Quality Level

200

assay

≥99% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white

solubility

methanol: 10 mg/mL, ethanol: 20 mg/mL (heating may be required)

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-

InChI key

DODQJNMQWMSYGS-QPLCGJKRSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

A cell-permeable, active metabolite of Tamoxifen (Cat. No. 579000) that acts as a potent inhibitor of PKC. It is more potent than the parent compound and inhibits PKC by modifying its catalytic domain. Also available as a 10 mM solution in EtOH (Cat. No. 508225).

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PKC
Product does not compete with ATP.
Reversible: no

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Gundimeda, U., et al. 1996. J. Biol. Chem. 271, 13504.
Ye, Q. and Bodell, W.J. 1996. Carcinogenesis 17, 1747.
Laser, R., et al. 1985. Eur. J. Cancer Clin. Oncol. 21, 985.
Jordan, V.C., et al. 1978. J. Toxicol. Environ. Health 4, 364.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jianping Zhang et al.
American journal of cancer research, 13(12), 6210-6225 (2024-01-08)
Estrogen receptor positive (ER+) breast cancer patients exhibit poorer responsiveness to nab-paclitaxel compared to ER negative (ER-) patients, with the underlying mechanisms remaining unknown. Caveolin 1 (CAV1) is a membrane invagination protein critical for the endocytosis of macromolecules including albumin-bound
David Earl Hostallero et al.
Genomics, proteomics & bioinformatics, 21(3), 535-550 (2023-02-13)
Prediction of the response of cancer patients to different treatments and identification of biomarkers of drug response are two major goals of individualized medicine. Here, we developed a deep learning framework called TINDL, completely trained on preclinical cancer cell lines
Daniel R Schmidt et al.
Communications medicine, 3(1), 108-108 (2023-08-10)
Genetically engineered mouse models (GEMMs) of cancer are powerful tools to study mechanisms of disease progression and therapy response, yet little is known about how these models respond to multimodality therapy used in patients. Radiation therapy (RT) is frequently used
Kusmardi Kusmardi et al.
F1000Research, 10, 902-902 (2021-10-26)
Background: Research in natural substances for their anticancer potential has become increasingly popular. Lunasin, a soybean protein, is known to inhibit cancer progression via various pathways.  The aim of this study was to investigate the effect of Lunasin Extract (LE)
Si Chen et al.
Molecular carcinogenesis, 62(2), 249-260 (2022-11-03)
Breast cancer is the most common cancer in women worldwide. Although tamoxifen (TAM), a selective estrogen receptor (ER) modulator, is widely used to treat ER-positive breast cancers, resistance to TAM remains a major clinical problem. NADPH-dependent cytochrome P450 reductase (POR) is
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service